Market Newsdesk

VANCOUVER, BC
, May 9, 2025 /PRNewswire/ – International Tower Hill Mines Ltd.  (the “Company”) – (TSX: ITH) (NYSE American: THM) today announced that it has filed its unaudited first quarter Financial Statements and associated Management Discussion and Analysis and Quarterly Report on Form 10-Q for the three-month period ended March 31, 2025.

Shareholders can obtain copies of the Company’s unaudited first quarter Financial Statements and associated Management Discussion and Analysis and Form 10-Q on SEDAR+ at: www.sedarplus.ca, EDGAR at www.sec.gov and on the Company’s website at: www.ithmines.com. The Company will also provide hard copies of these documents, free of charge, to shareholders who request a copy directly from the Company.

About International Tower Hill Mines Ltd.

International Tower Hill Mines Ltd. has a 100% interest in its Livengood Gold Project located along the paved Elliott Highway, 70 miles north of Fairbanks, Alaska.

On behalf of
International Tower Hill Mines Ltd.

(signed) Karl L. Hanneman
Chief Executive Officer

This news release is not, and is not to be construed in any way as, an offer to buy or sell securities in the United States.

View original content:https://www.prnewswire.com/news-releases/international-tower-hill-mines-files-2025-first-quarter-financial-results-302450875.html

SOURCE International Tower Hill Mines Ltd.

CAMBRIDGE, Mass.
, May 9, 2025 /PRNewswire/ — MetaVia Inc. (Nasdaq: MTVA) (“MetaVia“), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a private placement that MetaVia estimates will result in gross proceeds of approximately $10.0 million, before deducting the placement agent’s fees and other offering expenses payable by the company. MetaVia currently intends to use the net proceeds from the offering for working capital and corporate purposes, including to continue the clinical development of DA-1726 for the treatment of obesity.

The terms of the offering include an agreement to purchase (i) 9,479,345 shares of MetaVia’s common stock at a price of $0.71 per share, and (ii) 4,605,162 pre-funded warrants to purchase shares of MetaVia’s common stock at a price of $0.709 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per pre-funded warrant, and will be exercisable beginning on the effective date of receiving stockholder approval for the shares of MetaVia’s common stock issuable upon exercise of the pre-funded warrants. The private placement was priced at-the-market under Nasdaq rules, and the closing of the private placement is expected to occur on or about May 12, 2025, subject to customary closing conditions.

The offer and sale of the securities in the private placement, including the shares of common stock underlying the pre-funded warrants, are being made to certain institutional accredited investors in a transaction not involving a public offering pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act“), and Rule 506(b) of Regulation D promulgated thereunder, and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities to be issued in the private placement and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement with the Securities and Exchange Commission (“SEC“) or an applicable exemption from the registration requirements of the Securities Act and such other applicable state securities laws. MetaVia has agreed to file a registration statement with the SEC covering the resale of the shares of MetaVia common stock issued and underlying the pre-funded warrants in the private placement and to obtain stockholder approval for the shares of MetaVia common stock underlying the pre-funded warrants issued in the private placement.

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com. 

Forward Looking Statements

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “potential”, “intends”, “projects”, “plans”, “estimates” or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements, which include, among other statements, statements regarding the expected timing of the closing of the offering, the satisfaction of customary closing conditions related to the offering, the anticipated use of the net proceeds from the offering, the filing of a registration statement with the SEC, and obtaining stockholder approval for the shares of MetaVia common stock issued and underlying the pre-funded warrants in the private placement. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia’s ability to execute on its commercial strategy; MetaVia’s expectations regarding the sufficiency of its existing cash on hand to fund MetaVia’s operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia’s current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia’s contract manufacturers, clinical study partners and others involved in the development of MetaVia’s current and future product candidates; potential negative interactions between MetaVia’s product candidates and any other products with which they are combined for treatment; MetaVia’s ability to initiate and complete clinical trials on a timely basis; MetaVia’s ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia’s clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia’s stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia’s filings with the Securities and Exchange Commission, including MetaVia’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

MetaVia

Marshall H. Woodworth

Chief Financial Officer
+1-857-299-1033
[email protected]

Rx Communications Group


Michael Miller

+1-917-633-6086
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-10-0-million-private-placement-priced-at-the-market-under-nasdaq-rules-302450862.html

SOURCE MetaVia Inc.

Urges Shareholders to Vote on Bulldog’s GREEN Proxy Card at Tejon Annual Meeting of Shareholders

PALO ALTO, Calif.
, May 9, 2025 /PRNewswire/ — Glenbrook Capital Management (“Glenbrook” or “we”), a long-time shareholder of Tejon Ranch Co. (NYSE:TRC) (“Tejon” or the “Company”) and owner of approximately 1.1% of outstanding shares of the Tejon, thanks CalSTRS for its vote FOR both Item #4 to allow Tejon shareholders owning a combined 10% of outstanding shares to call a special meeting of shareholders and FOR Bulldog Capital’s state of nominees (“Bulldog’s Slate”) to the Tejon Board of Directors (the “Board”) on Bulldog’s GREEN Proxy Card.

“We are happy that CalSTRS has joined us, Bulldog and Harvey Capital in recognizing the urgent need for change to unlock value at Tejon for shareholders. We believe their votes FOR the shareholder proposal (“Item 4”) submitted by PFS Trust — which would enable Tejon shareholders owning a combined 10% of outstanding Tejon shares to call a special meeting — and FOR Bulldog’s Slate are aligned with the best interests of Tejon shareholders.

Importantly, casting votes using Bulldog’s GREEN Proxy Card enables cumulative voting and maximizes the impact of shares voted for Bulldog’s Slate. Accordingly, we intend to vote FOR Item 4and Bulldog’s Slate on the GREEN Proxy Card at the Tejon Annual Meeting of Shareholders scheduled for next Tuesday, May 13, 2025, and urge other shareholders to do the same.”

***

Media Contact: 

ASC Advisors 

Taylor Ingraham

[email protected]

203-992-1230

Investor Contact:
Richard Rudgley
President, Glenbrook Capital Management
[email protected]

Grover Wickersham

Chairman, Glenbrook Capital Management
415-601-1111    

Disclaimer and Cautionary Statement Regarding Forward-Looking Statements

This press release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein in any state to any person. This press release does not constitute a solicitation of authority to vote any proxy card at the Annual Meeting of Shareholders of Tejon and Glenbrook is not asking for your proxy card.

The information herein contains “forward-looking statements.” Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “potential,” “targets,” “forecasts,” “seeks,” “could,” “should” or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct or that any of the objectives, plans or goals stated herein will ultimately be undertaken or achieved. If one or more of such risks or uncertainties materialize, or if Glenbrook underlying assumptions prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward-looking statements should not be regarded as a representation by Glenbrook that the future plans, estimates or expectations contemplated will ever be achieved.

View original content:https://www.prnewswire.com/news-releases/glenbrook-welcomes-calstrs-support-of-pfs-trusts-shareholder-proposal-and-bulldogs-director-slate-302451052.html

SOURCE Glenbrook Capital Management

Agreement Marks First Step Towards Nextdoor’s Adoption and Deployment of IAS’s AI-driven Total Media Quality Product Suite

NEW YORK
, May 9, 2025 /PRNewswire/ — Integral Ad Science (Nasdaq: IAS), a leading global media measurement and optimization platform, today announced a strategic partnership with Nextdoor (NYSE: KIND), the essential neighborhood network. IAS will now power Nextdoor’s first-party brand safety tool as a provider of pre-bid Brand Safety and Suitability Optimization on the platform, assuring advertisers that impressions are delivered to brand suitable ad adjacencies.

IAS’s pre-bid Brand Safety and Suitability Optimization uses AI-driven Multimedia Technology to provide advertisers with an additional layer of third-party transparency and suitability for their Nextdoor campaigns. Through this partnership, advertisers with managed accounts can run ads on Nextdoor’s Newsfeed, reaching one-third of U.S. households, with the confidence that their ads will run in brand safe and suitable environments based on industry-aligned standards.

“This partnership represents a major milestone in bringing deeper transparency, trust, and control for advertisers spending on Nextdoor,” said Jim Egan, SVP of Business Development of IAS. “By combining IAS’s AI-driven Multimedia Technology with Nextdoor’s strong content moderation capabilities, we’re offering a new level of protection and performance for brands engaging in hyperlocal at scale advertising.”

IAS’s pre-bid Brand Safety and Suitability Optimization for Nextdoor provides advertisers with:

• Trusted Third-Party Control: Nextdoor’s brand safety tool, powered by IAS, enables advertisers to apply pre-bid blocking on their social campaigns, against 12 industry-aligned categories and 4 risk levels.
• Custom, Dynamic Control: Advertisers can avoid unsuitable content based on brand specific needs, across mobile and desktop web environments and more than 90 languages.
• Best-in-class Technology: IAS’s AI-driven Multimedia Technology, layered with Nextdoor’s proprietary moderation systems, enables advertisers to accurately classify content at scale through frame-by-frame analysis, combining image, audio, and text signals.

“At Nextdoor, trust and community go hand in hand—so when it comes to advertising, this isn’t optional, it’s essential,” said Michael Kiernan, Chief Revenue Officer at Nextdoor. “Partnering with Integral Ad Science brings a new layer of trusted, third-party transparency to our platform, giving advertisers the confidence to show up in the right place, at the right time, in front of the right neighbors.”

IAS and Nextdoor plan to continue to expand their partnership, with the general availability of Total Media Quality (TMQ) for Nextdoor, inclusive of industry-aligned Brand Safety & Suitability Measurement and Viewability and Invalid Traffic Measurement, expected to be available  in H2 2025. Through TMQ for Nextdoor, advertisers can validate their content adjacency with trusted third-party analysis aligned to industry frameworks, and remain confident that they are engaging with local users and maximizing campaign spend.

About Integral Ad Science
Integral Ad Science (IAS) is a leading global media measurement and optimization platform that delivers the industry’s most actionable data to drive superior results for the world’s largest advertisers, publishers, and media platforms. IAS’s software provides comprehensive and enriched data that ensures ads are seen by real people in safe and suitable environments, while improving return on ad spend for advertisers and yield for publishers. Our mission is to be the global benchmark for trust and transparency in digital media quality. For more information, visit integralads.com.

Media Contact: [email protected]

About Nextdoor
Nextdoor (NYSE: KIND) is the essential neighborhood network. Neighbors, public agencies and businesses use Nextdoor to connect around local information that matters in more than 345,000 neighborhoods across 11 countries. Nextdoor builds innovative technology to foster local community, and brands and businesses of all sizes use Nextdoor’s proprietary advertising platform to engage with neighborhoods at scale. Download the app and join the neighborhood at nextdoor.com. For more information and media assets, visit nextdoor.com/newsroom.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ias-announces-first-to-market-partnership-with-nextdoor-for-ai-powered-pre-bid-brand-safety-and-suitability-optimization-302450812.html

SOURCE Integral Ad Science, Inc.

INDIANAPOLIS and WEST LAFAYETTE, Ind., May 9, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned investment of up to $250 million in the collaboration over the next eight years. This partnership, which has the potential to be the largest ever industry-academic agreement of its kind in the United States, will seek to accelerate innovation at every stage of the pharmaceutical pipeline.

The Lilly-Purdue 360 Initiative aims to achieve several key goals, including discovering and accelerating the delivery of medicines to patients; bridging the gap between laboratory discoveries and clinical applications; creating more resilient, efficient and sustainable supply chains; and deploying innovative, scalable approaches to workforce development. The expanded collaboration is also expected to generate significant economic benefits for Indiana by creating a highly skilled workforce and fostering local innovation.

The earlier agreement, which had been set to expire in 2027, will now extend with four new projects added through 2032. Additionally, it will engage existing joint programs, such as Lilly Scholars at Purdue and the Lilly and Purdue Research Alliance Center (LPRC). Purdue will make space available for Lilly researchers on-site in West Lafayette. Purdue researchers will collaborate in Lilly facilities in Indianapolis and in Indiana’s LEAP Research and Innovation District.

“As potentially the largest single university-industry research agreement in American history, Lilly and Purdue are blazing a new trail to the endless frontier,” said Purdue University President Mung Chiang. “As for our state, when its largest company and the largest university expand collaboration at a scale never seen before, especially in the backdrop of Lilly’s manufacturing facility in LEAP, today marks a monumental watershed in the generation of jobs, workforce, and innovation along America’s Hard-Tech Corridor. We thank Lilly for its pioneering impact on health and medicine in our society and for what is now the largest single research funding, from public or private capital, in Purdue’s history.”

To achieve the initiative’s ambitious goals, Lilly and Purdue will concentrate on several key areas:

• Applying AI-powered tools to augment traditional drug discovery methods while leveraging advancements in machine learning and big data analytics to explore disease mechanisms and personalized treatments
• Facilitating technology-enabled approaches to accelerate potential treatments from Phase I clinical studies to regulatory approval and technology transfer into manufacturing — critical focus areas of the Lilly Medicine Foundry
• Incorporating robotics, AI, and data sciences to quickly scale manufacturing capacity more effectively, with improved compliance and greater sustainability
• Enhancing workforce development to ensure a strong talent pipeline to meet the demands of Lilly and other Indiana employers

“Accelerating the delivery of life-changing medicines demands a highly skilled workforce and continuous innovation across discovery, process development and manufacturing,” said David A. Ricks, Lilly’s chair and CEO. “Through this expanded collaboration with Purdue, we look forward to combining our strengths in advanced technologies and cutting-edge science to pioneer new methods of delivering next-generation medicines to advance human health.”

The Lilly-Purdue 360 Initiative supports Purdue’s One Health initiative, which advances knowledge and innovation related to animal, human, and plant well-being through novel interdisciplinary initiatives and partnerships with industry.

About Purdue University

Purdue University is a public research university leading with excellence at scale. Ranked among top 10 public universities in the United States, Purdue discovers, disseminates and deploys knowledge with a quality and at a scale second to none. More than 107,000 students study at Purdue across multiple campuses, locations and modalities, including more than 58,000 at our main campus in West Lafayette and Indianapolis. Committed to affordability and accessibility, Purdue’s main campus has frozen tuition 14 years in a row. See how Purdue never stops in the persistent pursuit of the next giant leap — including its comprehensive urban expansion, the Mitch Daniels School of Business, Purdue Computes and the One Health initiative — at https://www.purdue.edu/president/strategic-initiatives.

About Lilly 
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-plans-to-expand-purdue-university-collaboration-with-up-to-a-250-million-investment-to-accelerate-pharmaceutical-innovation-302451055.html

SOURCE Eli Lilly and Company

New trip matching tool uses AI to convert social media inspiration


into real-world travel plans—all within Instagram

SEATTLE
, May 9, 2025 /PRNewswire/ — Expedia® today announced Expedia® Trip Matching, a first-of-its-kind feature that allows travelers to seamlessly build an itinerary based on an Instagram Reel and then book directly on Expedia. Travelers can share any publicly available travel-related Reel—whether from content creators they follow or trending posts—directly with Expedia and receive customized itineraries, destination ideas, and travel tips based on the video. Powered by AI, this new experience transforms inspiration into real-world travel plans, making it easier than ever to book travel directly from Instagram.

“It’s no secret people are getting their news, inspiration and travel ideas from influencers and content creators, with a recent study showing that 80% of millennials rely on social media for travel decisions*,” said Jochen Koedijk, Chief Marketing Officer, Expedia Group. “We want to be where consumers get their inspiration, which is through social media. Now with Expedia® Trip Matching, travelers can seamlessly build an itinerary based on an Instagram Reel and book it directly on Expedia.”

How Expedia® Trip Matching works:

• Find inspiration: While scrolling Instagram, a user finds a Reel featuring a destination or experience they love.
• Share it with Expedia: They tap the share icon on the Reel, search for the @Expedia account, and send the video.
• Receive fast results: Expedia replies with AI-generated, personalized travel recommendations, itineraries, and trip-planning resources based on the video.
• Book when ready: Travelers can review and book directly from the customized itinerary—seamlessly bridging social discovery with real-world booking.

Expedia® Trip Matching is now open for beta access by visiting Expedia.com/tripmatching.com. The feature will be available to U.S. travelers in the upcoming weeks. Through the new trip matching feature, Expedia becomes the first OTA to integrate real-time, AI-powered travel planning directly into Instagram. The feature reflects the company’s commitment to innovation and meeting the next generation of travelers where they are—inspired, mobile, and social-first.

ABOUT EXPEDIA

Expedia
^® is one of the world’s leading full-service travel brands, with a mission of helping travelers get the most out of every trip they take by providing everything they need all in one place, ensuring they are getting the most out of every trip they take, and above all else, feel supported every step of the way.   

Our commitment to insights matched with our unprecedented scale allows us to understand our travelers better than anyone else, delivering exactly what they need, when they need it. Our personalized experiences, backed by incredible technology, enable us to deliver the widest selection of product offerings across accommodations, transportation, activities and experiences that help you get the most out of your journey.   

Use our mobile app or visit www.expedia.com to plan your journey with us.   

© 2025 Expedia, Inc., an Expedia Group company. All rights reserved. Expedia and the Expedia logo are trademarks of Expedia, Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners. CST# 2029030-50.
Follow Expedia on Instagram, TikTok, Pinterest, Twitter and YouTube. 

* Source: Klook Pulse study, November 2023

View original content to download multimedia:https://www.prnewswire.com/news-releases/expedia-launches-industry-first-feature-that-turns-instagram-reels-into-bookable-travel-itineraries-302450800.html

SOURCE Expedia